US gastroenterologists more in favor of biosimilars than rheumatology and dermatology counterparts. EXTON, PA., September 23, 2024 — Spherix Global
Biogen’s litifilimab “stands out as an especially strong competitor” to Benlysta and Saphnelo, according to Spherix Global Insights analysts. New
Despite favorable views on litifilimab, AbbVie’s Rinvoqand BMS’ Sotyktu capture the most prescriber interest for approval, accordingto Spherix Global Insights.
While reported use of Sanofi/Regeneron’s Dupixent has declined with the adoption of LEO’s Adbry, Pfizer’s Cibinqo, and AbbVie’s Rinvoq, the
Analysts expect the companies’ Vabysmo and Eylea HD to generate a combined $13.2 billion by 2030 in the vascular endothelial
Prior to the approvals and launches of Iqirvo and Livdelzi, US gastroenterologists notably favored the second to market Livdelzi as
New research conducted by Spherix Global Insights highlights opportunities for genetic therapies (Casgevy, Lyfgenia, Zynteglo) and emerging pipeline agents (including
With few treatment options for patients, hematologists look to pipeline agents such as Johnson & Johnson’s nipocalimab and Novartis’ ianalumab
US retinal specialists identify 4D Molecular Therapeutics’ 4D-150, Adverum Biotechnologies’ Ixo-vec, and Johnson & Johnson’s JNJ-1887 as most likely pipeline
Spherix Global Insights recently delved into the efficacy, patient quality of life, and symptom management of adalimumab vs secukinumab. Managing
Takeda’s resurrection of the once-rejected Eohilia appears to be paying off, with a survey of physicians finding the launch is in line
Impacts of Eohilia’s short-term 12-week label are still unfolding, but prescribers express interest in continuing consecutive treatment courses. EXTON, PA.,
